药明生物今日发布公告称,公司与默沙东达成协议,默沙东将以约5亿美元(约39亿港币)的总交易金额,收购药明海德在爱尔兰的疫苗工厂。公司预计本次交易将在2025年上半年满足惯例交割条件后完成。 交易对象为药明海德爱尔兰疫苗基地资产 本次交易涉及药明海德位于爱尔兰的疫苗工厂。根据数据,药明海德在2023年的收入为9.83亿元,净利润为3,830万元,占药明生物总净利润的1.1%。截至2024年11月30...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.